Literature DB >> 31111035

Subclinical Nasal and Lung Lymphocytosis in Ulcerative Colitis.

Maurizio Marvisi1, Laura Balzarini1, Chiara Mancini1, Sara Ramponi1, Chiara Marvisi1, Enrico Maffezzoni2.   

Abstract

BACKGROUND: Extraintestinal manifestations are common in ulcerative colitis (UC). Data regarding pulmonary and nasal mucosa involvement are sparse.
OBJECTIVES: The aim of the study was to evaluate, by using induced sputum (IS) and nasal cytology (NC), the cytological pattern of the lung and nose in patients with UC.
MATERIALS AND METHODS: We enrolled 15 consecutive subjects from the outpatient department with a recent diagnosis of UC. On the same day of enrollment, we performed a global spirometry, including a lung diffusing capacity test, IS analysis, and evaluation of NC.
RESULTS: IS analysis showed an increase in lymphocytes in UC patients when compared to those of controls (2.8 ± 0.9 vs. 0.2 ± 0.4%; p < 0.01). NC showed a similar increase in lymphocytes (12.5 ± 5.30 vs. 3.5 ± 4.0%; p < 0.01). We found a positive correlation between lymphocyte counts in IS and NC (r = 0.775; p < 0.001) and between lymphocytes in IS and NC and grade of intestinal inflammation (r = 0.603, p = 0.015; r = 0.60, p = 0.013).
CONCLUSIONS: Our data demonstrated that UC patients may have a subclinical nasal and lung lymphocytosis.

Entities:  

Keywords:  Extraintestinal manifestations; Inflammatory bowel disease; Lung involvement; Lymphocytes; Nasal involvement; Ulcerative colitis

Year:  2019        PMID: 31111035      PMCID: PMC6501544          DOI: 10.1159/000495985

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  16 in total

1.  Genetics and phenotypes in inflammatory bowel disease.

Authors:  Joana Torres; Jean-Frédéric Colombel
Journal:  Lancet       Date:  2015-10-18       Impact factor: 79.321

Review 2.  Extraintestinal manifestations and complications in IBD.

Authors:  Claudia Ott; Jürgen Schölmerich
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-09       Impact factor: 46.802

Review 3.  Patterns of airway involvement in inflammatory bowel diseases.

Authors:  Ilias Papanikolaou; Konstantinos Kagouridis; Spyros A Papiris
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

4.  Is it possible to detect ulcerative colitis-related respiratory syndrome early?

Authors:  F Karadag; M H Ozhan; E Akçiçek; O Günel; H Alper; A Veral
Journal:  Respirology       Date:  2001-12       Impact factor: 6.424

Review 5.  Pulmonary manifestations of inflammatory bowel disease.

Authors:  Xiao-Qing Ji; Li-Xia Wang; De-Gan Lu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

6.  Induced sputum in patients with newly diagnosed sarcoidosis: comparison with bronchial wash and BAL.

Authors:  R D'Ippolito; A Foresi; A Chetta; A Casalini; A Castagnaro; C Leone; D Olivieri
Journal:  Chest       Date:  1999-06       Impact factor: 9.410

7.  Induced sputum eosinophilia in ulcerative colitis patients: the lung as a mirror image of intestine?

Authors:  Elizabeth Fireman; Farid Masarwy; Gabi Groisman; Moshe Shtark; Yael Kopelman; Shmuel Kivity; Zvi Fireman
Journal:  Respir Med       Date:  2009-02-20       Impact factor: 3.415

8.  When allergic rhinitis is not only allergic.

Authors:  Matteo Gelardi; Cosimo Russo; Maria Luisa Fiorella; Raffaele Fiorella; Giorgio Walter Canonica; Giovanni Passalacqua
Journal:  Am J Rhinol Allergy       Date:  2009 May-Jun       Impact factor: 2.467

Review 9.  Pulmonary-intestinal cross-talk in mucosal inflammatory disease.

Authors:  S Keely; N J Talley; P M Hansbro
Journal:  Mucosal Immunol       Date:  2011-11-16       Impact factor: 7.313

10.  Toll-like receptor 6 stimulation promotes T-helper 1 and 17 responses in gastrointestinal-associated lymphoid tissue and modulates murine experimental colitis.

Authors:  M E Morgan; P J Koelink; B Zheng; M H M G M den Brok; H J G van de Kant; H W Verspaget; G Folkerts; G J Adema; A D Kraneveld
Journal:  Mucosal Immunol       Date:  2014-03-26       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.